Bardellini E, Amadori F, Conti G, Veneri F, Majorana A. Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease. Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24 (2):e190-4.
doi:10.4317/medoral.22699
http://dx.doi.org/doi:10.4317/medoral.22699
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________
References
|
1.
Travnik R, Beckers M, Wolff D, Holler E, Landthaler M, Karrer S.
Graft-versus-Host Disease (GvHD) - an update. Part 1: Pathophysiology,
clinical features and classification of GvHD. Hautarzt. 2011;62:139–54. |
|
|
|
|
|
2.
Margaix-Mu-oz M, Bagán JV, Jiménez Y, Sarrión MG, Poveda-Roda R.
Graft-versus-host disease affecting oral cavity. A review. J Clin Exp Dent.
2015;7:138-45. |
|
|
|
|
|
3.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ. National
Institutes of Health consensus development project on criteria for clinical
trials in chronic graft-versus-host disease: I. Diagnosis and staging working
group report. Biol Blood Marrow Transplant. 2005;11:945–56. |
|
|
|
|
|
4.
Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft-versus-host
disease: current pathogenesis, therapy, and research. Oral Dis
2013;19:327-46. |
|
|
|
|
|
5.
Treister NS, Cook EF Jr, Antin J, Lee SJ, Soiffer R, Woo SB. Clinical
evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow
Transplant. 2008;14:110-5. |
|
|
|
|
|
6.
Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu OH, WuT, et al. Changes in
salivary proteome following allogeneic hematopoietic stem cell
transplantation. Exp Hematol. 2007;35:184–92. |
|
|
|
|
|
7.
Nagler RM, Nagler A. Salivary gland involvement in graft-versus-host disease:
the underlying mechanism and implicated treatment. Isr Med Assoc J.
2004;6:167-72. |
|
|
|
|
|
8.
Imanguli MM, Atkinson JC, Mitchell SA, Avila DN, Bishop RJ, Cowen EW.
Salivary gland involvement in chronic graft-versus-host disease: prevalence,
clinical significance, and recommendations for evaluation. Biol Blood Marrow Transplant
2010;16:1362–9. |
|
|
|
|
|
9.
Vissink A, Schaub RM, van Rijn LJ, Gravenmade EJ, Panders AK, Vermey A. The
efficacy of mucin-containing artificial saliva in alleviating symptoms of
xerostomia. Gerodontology. 1987;6:95–101. |
|
|
|
|
|
10.
Gravenmade EJ, Vissink A. Mucin-containing lozenges in the treatment of
intraoral problems associated with Sjögren's syndrome. A double-blind
crossover study in 42 patients. Oral Surg Oral Med Oral Pathol.
1993;75:466–71. |
|
|
|
|
|
11.
van der Reijden WA, van der Kwaak H, Vissink A, Veerman EC, Amerongen AV.
Treatment of xerostomia with polymer-based saliva substitutes in patients
with Sjögren's syndrome. Arthritis Rheum. 1996;39:57–63. |
|
|
|
|
|
12.
Regelink G, Vissink A, Reintsema H, Nauta JM. Efficacy of a synthetic polymer
saliva substitute in reducing oral complaints of patients suffering from
irradiation-induced xerostomia. Quintessence Int. 1998;29:383–8. |
|
|
|
|
|
13.
Navazesh M, Christensen CM. A comparison of whole mouth resting and stimulated
salivary measurement procedures. J Dent Res. 1982;61:1158–62. |
|
|
|
|
|
14.
Nakhleh RE, Miller W, Snover DC. Significance of mucosal vs salivary gland
changes in lip biopsies in the diagnosis of chronic graft-vs-host disease.
Arch Pathol Lab Med. 1989;113:932-4. |
|
|
|
|
|
15.
Nagler RM, Nagler A. Major salivary gland involvement in graft-versus-host
disease: considerations related to pathogenesis, the role of cytokines and
therapy. Cytokines Cell Mol Ther. 1999;5:227-32. |
|
|
|
|
|
16.
Van der Putten GJ, Brand HS, Schols JM, de Baat C. The diagnostic suitability
of a xerostomia questionnaire and the association between xerostomia,
hyposalivation and medication use in a group of nursing home residents. Clin
Oral Investig. 2011;15:185-92. |
|
|
|
|
|
17. Villa A, Connel CL, Abati S. Diagnosis and management of xerostomia and hyposalivation. Ther Clin Risk Manag. 2015:45-51. |
|
|
|
|
|
18.
Dawes C. How much saliva is enough for avoidance of xerostomia? Caries Res.
2004;38:236-40. |
|
|
|
|
|
19.
Humphrey SP, Williamson RT. A review of saliva: normal composition, flow and
function. J Prosthet Dent. 2001;85:162-9. |
|
|
|
|
|
20.
Pedersen AM, Bardow A, Jensen SB, Nauntofte B. Saliva and gastrointestinal functions
of taste, mastication, swallowing and digestion. Oral Dis. 2002;8:117-29. |
|
|
|
|
|
21. Sreebny LM, Vissink A. Dry Mouth: the malevolent symptom. A clinical guide. Ames: Wiley-Blackwell; 2010. |
|
|
|
|
|
22.
Watanabe M, Yamada C, Komagata Y, Kikuchi H, Hosono H, Itagaki F. New
low-dose liquid pilocarpine formulation for treating dry mouth in Sjögren's
syndrome: clinical efficacy, symptom relief, and improvement in quality of
life. J Pharm Health Care Sci. 2018;4:4. |
|
|
|
|
|
23.
Visvanathan V, Nix P. Managing the patient presenting with xerostomia: a
review. Int J Clin Pract. 2010;64:404-7. |
|
|
|
|
|
24.
Gambon DL, Brand HS, Nieuw Amerongen AV. The erosive potential of candy
sprays. Br Dent J. 2009;206:530-1. |
|
|
|
|
|
25.
Gómez-Moreno G, Guardia J, Aguilar-Salvatierra A, Cabrera-Ayala M,
Maté-Sánchez de-Val JE, Calvo-Guirado JL. Effectiveness of malic acid 1% in patients
with xerostomia induced by antihypertensive drugs. Med Oral Patol Oral Cir
Bucal. 2013;18:49-55. |
|
|
|
|
|
26.
da Mata AD, da Silva Marques DN, Silveira JM, Marques JR, de Melo Campos
Felino ET, Guilherme NF. Effects of gustatory stimulants of salivary
secretion on salivary pH and flow: a randomized controlled trial. Oral Dis.
2009;15:220–8. |
|
|
|
|
|
27.
Martín-Piedra MA, Gómez-Moreno G, Herrera D, Aguilar-Salvatierra A.
Effectiveness of a recent topical sialogogue in the management of
drug-induced xerostomia. J Clin Exp Dent. 2011;3:268-73. |
|